Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer-Reference-Cited by-同舟云学术

Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer

Published:2016-03-11 Issue:1 Volume:16 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Quéré Gilles,Descourt Renaud,Robinet Gilles,Autret Sandrine,Raguenes Odile,Fercot Brigitte,Alemany Pierre,Uguen Arnaud,Férec Claude,Quintin-Roué Isabelle,Le Gac Gérald

Funder

Ligue Contre le Cancer (FR)

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-016-2249-6

Reference35 articles.

1. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:3543–51.

2. Toschi L, Cappuzzo F. Impact of biomarkers on non-small cell lung cancer treatment. Target Oncol. 2010;5:5–17.

3. Soria J-C, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon J-P. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24:20–30.

4. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:1394–400.

5. Jackman DM, Miller VA, Cioffredi L-A, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:5267–73.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MAPKAPK5-AS1/miR-515-5p/CAB39 Axis Contributes to Non-small Cell Lung Cancer Cell Proliferation and Migration;Molecular Biotechnology;2023-03-03

2. Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance;Discover Oncology;2021-11-08

3. Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing;Journal of Thoracic Oncology;2021-07

4. Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer;Translational Lung Cancer Research;2021-07

5. Long non‐coding RNA CASC19 facilitates non‐small cell lung cancer cell proliferation and metastasis by targeting the miR‐301b‐3p/LDLR axis;The Journal of Gene Medicine;2020-09-27